Page content

Page breadcrumb

9.4 Platelet disorders

First line drugs Second line drugs Specialist drugs Secondary care drugs
First line drugs Second line drugs Specialist drugs Secondary care drugs
Recommended in both primary and secondary care Alternatives (often in specific conditions) in both primary and secondary care; Where a specialist input is needed (see introduction for definition) Prescribing principally within secondary care only

Traffic light status (TLS) explained:

  • Green: Routine prescribing within licensed indication
  • Amber 1: specialist recommendation followed by GP initiation and continuation
  • Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
  • Amber 3: specialist initiation and stabilisation followed by GP continuation
  • Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
  • Red: Hospital or specialist prescribing only
  • Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

 

9.4 Platelet disorders

 

9.4.1 Essential thrombocythaemia

 

Anagrelide

  • Capsules 500 micrograms  

 

 

9.4.2 Idiopathic thrombocytopenic purpura

 

Eltrombopag

  • Tablets 25mg, 50mg

Notes:

Drug Safety Update. July 2018. Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results

Advice for healthcare professionals:
• eltrombopag is highly coloured (reddish-brown) and can cause serum discolouration and interference with the test results of creatinine and bilirubin
• be aware that interference with bilirubin (falsely low/normal results) and creatinine (falsely high/normal results) may occur in patients taking eltrombopag
• if bilirubin and/or creatinine laboratory results are inconsistent with clinical observations, request re-testing using another method to determine the validity of the result
• the laboratory may consider susceptibility to serum discolouration and other factors that may be relevant when selecting an alternative test method
• report suspected adverse drug reactions, including any harm that
occurs from a medicine interfering with laboratory test results, to the Yellow Card Scheme

 

Romiplostim

  • Injection, powder for reconstitution 250 microgram vial

Notes:

 

 

 

 

 

Traffic light status (TLS) explained:

  • Green: Routine prescribing within licensed indication
  • Amber 1: specialist recommendation followed by GP initiation and continuation
  • Amber 2: specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation
  • Amber 3: specialist initiation and stabilisation followed by GP continuation
  • Amber SCG: specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline
  • Red: Hospital or specialist prescribing only
  • Double Red: These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.

 

 

 

Return to Chapter: 9. Nutrition and Blood

Last updated by: Dupe Fagbenro on 16-01-2019 14:08